Patents

Search tools Text Classification Chemistry Measure Numbers Full documents Title Abstract Claims All Any Exact Not Add AND condition These CPCs and their children These exact CPCs Add AND condition
Exact Exact Batch Similar Substructure Substructure (SMARTS) Full documents Claims only Add AND condition Add AND condition
Application Numbers Publication Numbers Either Add AND condition

Erection-inducing method and compositions

Classifications

A61K38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
View 7 more classifications

Landscapes

Health & Medical Sciences Life Sciences & Earth Sciences
Show more

LT3544B

Lithuania

Download PDF Find Prior Art Similar
Other languages
English
Lithuanian
Inventor
Thomas Gerstenberg
Jan Fahrenkrug
Bent Ottesen
Worldwide applications
1989 US 1990 IL RU CA BR AU EP WO DE DK ES JP AT RO HU SK CZ 1992 NO KR FI 1993 LV GE LT
Application LTIP1579A events
1993-12-10
Application filed by Senetek Plc
1995-06-26
Publication of LTIP1579A
1995-11-27
Publication of LT3544B
Info
Patent citations (6)
Non-patent citations (1)
Cited by (39)
Legal events
Similar documents
Priority and Related Applications
External links
Espacenet
Global Dossier
Discuss

Patent Citations (6)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
US3898329A * 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
DE3637157A1 * 1985-11-01 1987-05-21 Byk Gulden Lomberg Chem Fab Arzneimittel zur behandlung erektiler dysfunktionen
JPS62246595A * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4939224A * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
IL87055A * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
* Cited by examiner, † Cited by third party

Non-Patent Citations (1)

Title
AUTORIUS: "Pharmacologicar basis of therapeuthies"
* Cited by examiner, † Cited by third party

Cited By (39)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
US5447912A * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5242391A * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DE4117249C2 * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
US5565466A * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5482039A * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5583144A * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5731339A * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5932538A * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6294517B1 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5994294A * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20050065161A1 * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6432401B2 * 2000-05-12 2002-08-13 Novalar Pharmaceuticals, Inc. Local anesthetic methods and kits
US20030004170A1 * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
US5947901A 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5942545A * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6011043A * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6482426B1 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6706682B2 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6730065B1 * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6211156B1 * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
US6650943B1 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
US20060211753A1 * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6885895B1 * 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
ES2363738T3 2005-03-07 2011-08-12 Mondobiotech Ag Formulación de aviptadil.
CN101384272B 2005-12-20 2013-05-01 杜克大学 用于递送具有增强的药理性质的活性剂的方法和组合物
US8841255B2 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2307038A4 2008-06-27 2013-03-27 Univ Duke ELASTIC PEPTIDES COMPREHENSIVE THERAPEUTIC AGENTS
RU2589255C2 * 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Модифицированные вазоактивные интестинальные пептиды
US9913748B2 2009-10-30 2018-03-13 Avner Spector Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
ES2669190T3 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
GB201221032D0 * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
GB201221046D0 * 2012-11-22 2013-01-09 Mens Health Ltd Method of diagnosis
CA2947982C 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
EP3256151B1 2015-02-09 2020-08-05 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2019102310A1 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions
* Cited by examiner, † Cited by third party, ‡ Family to family citation

Similar Documents

Publication Publication Date Title
RU2098120C1 1997-12-10 Фармацевтическая композиция для индуцирования эрекции у мужчин (варианты)
US5447912A 1995-09-05 Erection-inducing methods and compositions
Zorgniotti et al. 1985 Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence
Wespes et al. 1993 Venous impotence: pathophysiology, diagnosis and treatment
JP3310982B2 2002-08-05 男性の勃起機能不全を改善するための剤形及び方法
Gerstenberg et al. 1992 Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure
Earle et al. 1990 Prostaglandin E1 therapy for impotence, comparison with papaverine
Nellans et al. 1987 Pharmacological erection: diagnosis and treatment applications in 69 patients
US6187790B1 2001-02-13 Use of cilostazol for treatment of sexual dysfunction
Buvat et al. 1986 Venous incompetence: critical study of the organic basis of high maintenance flow rates during artificial erection test
Keogh et al. 1989 Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial
CA1338555C 1996-08-27 Agents for treatment of male impotence
Earle et al. 1992 The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury
US6110489A 2000-08-29 Use of quinolines and quinolones to treat male erectile dysfunction
JPH07506333A 1995-07-13 勃起機能不全症治療用ピリジルグアニジン化合物
Vickers et al. 1992 The current cavernosometric criteria for corporovenous dysfunction are too strict
US6132753A 2000-10-17 Treatment of sexual dysfunction in certain patient groups
Knispel et al. 1992 Influence of cause on choice of therapy in 174 patients with erectile dysfunction
US6303135B1 2001-10-16 Use of quinolines and quinolones to treat male erectile dysfunction
Fouda et al. 1989 Priapism: an avoidable complication of pharmacologically induced erection
Iacono et al. 1993 Evaluation of penile deep arteries in psychogenic impotence by means of duplex ultrasonography
HK1011292B 2002-09-13 Erection-inducing methods and compositions
Mooradian et al. 1989 Biweekly intracavernous administration of papaverine for erectile dysfunction
US20030105128A1 2003-06-05 Treatment of sexual dysfunction in certain patient groups
Jantos et al. 1988 Pharmacocavernosography in the evaluation of erectile failure

Priority And Related Applications

Applications Claiming Priority (1)

Application Filing date Title
US07/408,754 1989-09-18 Erection-inducing methods and compositions

Legal Events

Date Code Title Description
2011-07-25 MM9A Lapsed patents

Effective date: 20101210

Concepts

machine-extracted
Download Filter table
Name Image Sections Count Query match
mixture title,claims,abstract,description 53 0.000
inductive effect title,claims,abstract,description 12 0.000
method title,abstract,description 23 0.000
impotence claims,abstract,description 83 0.000
Atherosclerosis claims,abstract,description 40 0.000
neurogenic effect claims,abstract,description 26 0.000
psychogenic effect claims,abstract,description 21 0.000
phentolamine claims,abstract,description 18 0.000
phentolamine claims,abstract,description 18 0.000
Neuropeptides claims,abstract,description 16 0.000
Neuropeptides claims,abstract,description 15 0.000
processed proteins & peptides claims,abstract,description 14 0.000
prazosin claims,abstract,description 9 0.000
prazosin claims,abstract,description 9 0.000
histidine claims,abstract,description 6 0.000
invicorp claims,abstract,description 6 0.000
Vasoactive Intestinal Peptide claims,abstract,description 5 0.000
Vasoactive Intestinal Peptide claims,abstract,description 5 0.000
stimulation claims,description 32 0.000
injection claims,description 31 0.000
injection claims,description 31 0.000
sexual effect claims,description 29 0.000
alpha blocker claims,description 22 0.000
induction claims,description 19 0.000
erectile effect claims,description 18 0.000
Delivery claims,description 16 0.000
vaginal delivery claims,description 16 0.000
treatment claims,description 15 0.000
corpus cavernosum claims,description 8 0.000
solution claims,description 8 0.000
L-methionine claims 2 0.000
Peptide PHI claims 2 0.000
Peptide PHI claims 2 0.000
methionine claims 2 0.000
peptide histidine methionine claims 2 0.000
analeptic agent claims 1 0.000
L-methioninamide abstract,description 4 0.000
adrenergic antagonist abstract,description 4 0.000
histidyl group abstract,description 4 0.000
Homo sapiens Vasoactive intestinal peptide abstract,description 2 0.000
c-terminal region abstract 3 0.000
intracavernous injection abstract 3 0.000
penetration abstract 2 0.000
stimulating effect abstract 2 0.000
penile erection abstract 1 0.000
Show all concepts from the description section
Data provided by IFI CLAIMS Patent Services